TOKYO, Mar 23 (Pulse News Wire) – Aska Pharmaceutical Holdings CO.,LTD. (4886.T) announced the establishment of its long-term vision “ASKA VISION 2035,” targeting sustainable growth through 2035.
Concurrently, the company unveiled its initial three-year execution plan, the “Mid-Term Business Plan 2028,” aiming to achieve revenue of ¥85.00 billion by fiscal year 2028. Key strategies outlined in the mid-term plan include reinforcing domestic pharmaceutical operations, advancing drug discovery efforts, expanding global presence, growing animal health initiatives, and expanding diagnostic services.
The company also emphasized capital efficiency and governance improvements to support these goals. Details of the plans will be disclosed during the earnings briefing scheduled for May 20.
🟡 Confidence: Standard AI-translated content.